D.A. Davidson & CO. Invests $1.77 Million in Denali Therapeutics Inc. $DNLI

Key Points

• D.A. Davidson & CO. opened a new position in Denali Therapeutics, buying 106,933 shares valued at about $1.77 million, equal to roughly 0.07% of the company at quarter-end.
• Institutional ownership is high at 92.92%, and other recent moves include Foresite Capital's new $14.52 million stake and sizable increases by Aberdeen and Principal, signaling rising institutional interest.
• Denali is a clinical‑stage biotech with a $2.90 billion market cap, negative EPS (last quarter -$0.73), a 12‑month price range of $12.58–$23.77, and a consensus analyst rating of "Moderate Buy" with a target of $35 after several recent target increases to $34–$41.

D.A. Davidson & CO. acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 106,933 shares of the company's stock, valued at approximately $1,765,000. D.A. Davidson & CO. owned about 0.07% of Denali Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in DNLI. Foresite Capital Management VI LLC purchased a new stake in Denali Therapeutics in the third quarter worth $14,520,000. AlphaQuest LLC increased its stake in Denali Therapeutics by 224.1% in the third quarter. AlphaQuest LLC now owns 74,422 shares of the company's stock worth $1,081,000 after purchasing an additional 51,458 shares during the period. Aberdeen Group plc increased its stake in Denali Therapeutics by 23.4% in the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company's stock worth $16,169,000 after purchasing an additional 210,835 shares during the period. Principal Financial Group Inc. increased its stake in Denali Therapeutics by 18.5% in the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company's stock worth $18,458,000 after purchasing an additional 198,207 shares during the period. Finally, Capricorn Fund Managers Ltd purchased a new stake in Denali Therapeutics in the fourth quarter worth $1,027,000. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Price Performance

DNLI opened at $18.30 on Friday. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $23.77. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The business's fifty day simple moving average is $20.26 and its 200-day simple moving average is $18.77. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -6.16 and a beta of 1.00.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the company posted ($0.67) EPS. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Robert W. Baird increased their target price on Denali Therapeutics from $32.00 to $34.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 7th. Stifel Nicolaus increased their target price on Denali Therapeutics from $34.00 to $41.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. The Goldman Sachs Group increased their target price on Denali Therapeutics from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. BTIG Research increased their target price on Denali Therapeutics from $36.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Denali Therapeutics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $35.00.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.